BUZ INVESTORS PRESS RELEASE TAUG Discloses Personal Investment Tauriga Sciences Inc. ( OTC PINK : TAUG ) (“Tauriga” or “the Company”), a company engaged in the building of life sciences businesses and technologies, has today announced that is Chief Executive Officer (“CEO”), Mr. Seth M. Shaw (“Mr. Shaw”), has made a personal investment into the Company totaling $95,000 USD at this time. This personal investment was structured as an equity Private Placement at a price of $0.00125 (“one eighth of one cent”), for a total of 76,000,000 shares (a Form 4 reflecting this insider purchase will be filed within the next several business days). The Company will utilize this infusion of working capital for general and administrative purposes; these 76,000,000 shares will not be issued until the Company has successfully amended its Shares Authorized.
Tauriga’s CEO, Seth M. Shaw, expressed, “At this time, I believe it is of great importance to demonstrate to shareholders my unwavering commitment to both restoring and creating long term shareholder value. This $95,000 USD will help the Company satisfy some short term commitments & invoices and enable Tauriga to approach the second half of Calendar Year 2017 with a greater degree of strength, flexibility, and confidence.”
ABOUT TAURIGA SCIENCES, INC.
Tauriga Sciences, Inc. ( OTC PINK : TAUG ) is a fully reporting life sciences company engaged in the development, marketing, distribution and potential licensing of a broad array of products and technologies that may help individuals who are affected by muscle tension. The Company has already identified potential products and technologies of interest and is actively working towards the goal of creating an innovative product line to launch the business activities of ColluMauxil Therapeutics LLC (The Company’s previously announced new planned wholly owned subsidiary). The Company believes that one of its most important strengths is its access to and relationships with potentially substantial distribution systems and networks. The Company intends to capitalize on distribution opportunities and will continually update shareholders on such developments. The Company is also prosecuting (as Plaintiff) its ongoing malpractice lawsuit against its predecessor audit firm, for which it’s seeking monetary damages in excess of $4,500,000 USD.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Any securities offered or issued in connection with the above-referenced merger and/or investment have not been registered, and will be offered pursuant to an exemption from registration.